All Categories
Journal of Clinical Oncology Publishes Significant Evidence in Advancing...
The validation study shows no evidence of algorithmic bias. The development of the model may help mitigate the risk of racial [...]
Melvin L.K. Chua, FRCR, PhD, FASCO, on validation of...
Data presented at the American Society for Radiation Oncology 67th Annual Meeting validated the performance of the ArteraAI P [...]
Artera Unveils Four Presentations at ASTRO 2025 Illustrating its...
SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predi [...]
FDA Approves AI Tool to Transform Prostate Cancer Care...
Prostate cancer is one of the most common cancers affecting men in the United States, and it comes with a heavy price tag. Ne [...]
Positioning & Distribution Will Determine the Winning Healthcare AI...
In a crowded healthcare AI market, the winners will be those that control key leverage points — where data is created, workfl [...]
Artera Product Webinar – August 2025
The ArteraAI Prostate Test is transforming the risk stratification landscape for treating prostate cancer. For lower-risk pat [...]
AI Tools Speed Prostate Cancer Decisions With Faster Results
FDA-authorized artificial intelligence (AI) tools have the potential to help patients with prostate cancer get clearer answer [...]
Across the Prostate Cancer Continuum: Translating ArteraAI’s Biopsy Model...
Since launching the ArteraAI Prostate Test, Artera has used multimodal artificial intelligence (MMAI) algorithms to help thou [...]